- Home
- HSTM vs GHRS Comparison
HSTM vs GHRS Comparison
Compare HSTM & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HSTM
- GHRS
- Stock Information
- Founded
- HSTM 1990
- GHRS 2018
- Country
- HSTM United States
- GHRS Ireland
- Employees
- HSTM N/A
- GHRS N/A
- Industry
- HSTM Computer Software: Programming Data Processing
- GHRS Biotechnology: Pharmaceutical Preparations
- Sector
- HSTM Technology
- GHRS Health Care
- Exchange
- HSTM Nasdaq
- GHRS Nasdaq
- Market Cap
- HSTM 846.5M
- GHRS 930.8M
- IPO Year
- HSTM 2000
- GHRS 2021
- Fundamental
- Price
- HSTM $27.10
- GHRS $16.49
- Analyst Decision
- HSTM Hold
- GHRS Strong Buy
- Analyst Count
- HSTM 2
- GHRS 8
- Target Price
- HSTM $29.00
- GHRS $30.63
- AVG Volume (30 Days)
- HSTM 182.3K
- GHRS 182.0K
- Earning Date
- HSTM 07-21-2025
- GHRS 09-02-2025
- Dividend Yield
- HSTM 0.47%
- GHRS N/A
- EPS Growth
- HSTM 8.37
- GHRS N/A
- EPS
- HSTM 0.63
- GHRS N/A
- Revenue
- HSTM $292,371,000.00
- GHRS N/A
- Revenue This Year
- HSTM $5.00
- GHRS N/A
- Revenue Next Year
- HSTM $5.20
- GHRS N/A
- P/E Ratio
- HSTM $42.34
- GHRS N/A
- Revenue Growth
- HSTM 3.36
- GHRS N/A
- 52 Week Low
- HSTM $25.72
- GHRS $6.00
- 52 Week High
- HSTM $34.24
- GHRS $20.50
- Technical
- Relative Strength Index (RSI)
- HSTM 43.17
- GHRS 70.04
- Support Level
- HSTM $26.60
- GHRS $15.25
- Resistance Level
- HSTM $27.60
- GHRS $15.54
- Average True Range (ATR)
- HSTM 0.50
- GHRS 1.09
- MACD
- HSTM 0.01
- GHRS 0.31
- Stochastic Oscillator
- HSTM 37.62
- GHRS 93.92
About HSTM HealthStream Inc.
HealthStream Inc provides workforce and provider solutions for healthcare organizations. Its reportable segments include Workforce Solutions and Provider Solutions. Workforce development solutions consist of SaaS, subscription-based products that are used by healthcare organizations. Its Provider Solutions products offer healthcare organizations software applications for administering and tracking provider credentialing, privileging, call center and enrollment activities. The company generates a majority of its revenue from Subscription Services.
About GHRS GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.